New MS Treatment Shows Promise in Trial

By Amy Norton HealthDay Reporter

An experimental antibody therapy for multiple sclerosis can cut symptom flare-ups by half, versus a standard treatment, a new clinical trial has found.

The drug, called ublituximab, beat a standard oral medication for MS in reducing patients’ relapses — periods of new or worsening symptoms. It also proved better at preventing areas of inflammatory damage in the brain.

Ublituximab is not yet approved for treating MS; the U.S. Food and Drug Administration is reviewing the trial…